Projecting Dupilumab's Fit in COPD

News
Video

Ahead of the anticipated FDA decision in September, an expert panel reviews the promising data and unique role dupilumab may have in COPD.

In the second segment of this HCPLive Special Report – RX Reviews on chronic obstructive pulmonary disease (COPD) drug development, panel moderator David Mannino, MD, chief medical officer of the COPD Foundation and professor at the University of Kentucky, discusses the supporting trial data for dupilumab (Dupixent) as a treatment for particular patients with COPD, with investigator Stephanie Christenson, MD, associate professor of medicine at the University of California, San Francisco.

The US Food and Drug Administration (FDA) is expected to rule on a supplemental application from Sanofi & Regeneron to indicate the interleukin 4 and 13 (IL-4; IL-13) inhibitor dupilumab as a treatment for adults with uncontrolled COPD and type 2 inflammation. Dupilumab, a preeminent biologic therapy in the utility of type 2 inflammatory disease management, was investigated by Christenson and colleagues in the pivotal BOREAS & NOTUS trials for COPD outcomes including exacerbation reduction versus maximum-standard triple-therapy inhaler medication.

Christenson and Mannino additionally discussed the role of type 2 inflammation in COPD pathophysiology and symptoms, what may be the practical utility of targeted biologics like dupilumab in the field, and the significance of achieving reduced COPD exacerbations with therapy.

Check out the entire 3-part Special Report series, ‘COPD: New Therapy Breakthroughs’:

Part 1: What the Ensifentrine FDA Approval Means for COPD

Part 2: Projecting Dupilumab's Fit in COPD

Part 3: A Promising Pipeline for COPD

Our Moderator:

David M. Mannino, MD, Chief Medical Officer and Co-Founder of the COPD Foundation, and Professor of Internal Medicine, Pulmonary, Critical Care and Sleep Medicine at the University of Kentucky.

Our Panelists:

Antonio Anzueto, MD, Professor of Medicine and Section Chief of Pulmonary at South Texas Veterans Healthcare System.

Stephanie Christenson, MD, Associate Professor of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine at University of California, San Francisco.

References

  1. Kunzmann K. FDA Extends Dupilumab COPD Decision to September 2024. HCPLive. Published May 31, 2024. https://www.hcplive.com/view/fda-extends-dupilumab-copd-decision-september-2024
  2. Campbell P. NOTUS Trial Confirms Dupixent Benefit in COPD with Type 2 Inflammation. HCPLive. Published May 20, 2024. https://www.hcplive.com/view/notus-trial-confirms-dupixent-benefit-in-copd-with-type-2-inflammation
  3. Smith T. Surya Bhatt, MD: Findings on Dupilumab for Patients with COPD, Type 2 Inflammation. HCPLive. Published February 27, 2024. https://www.hcplive.com/view/surya-bhatt-findings-on-dupilumab-for-patients-with-copd-type-2-inflammation
Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
4 KOLs are featured in this series
4 KOLs are featured in this series
Video 4 - Featuring 3 KOLs in, "Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease "
Video 3 - Featuring 3 KOLs in, "How important is transmural healing as a treatment target in UC and CD?   Where does intestinal ultrasound fit in CD management?  "
4 KOLs are featured in this series
4 KOLs are featured in this series
A panel of 3 experts on COPD
© 2024 MJH Life Sciences

All rights reserved.